Phase 2 Start~month

Phase 2 Start: A Phase 1/2 Open-Label Intrathecal Administration of TSHA-105 to Determine the Safety and Efficacy i

Indication
SLC13A5 Citrate Transporter Disorder

Other upcoming events for GHRS

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immu
Phase 3 ReadoutPhase 3 Topline: Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: V
Phase 2 StartPhase 2 Start: Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controll
Phase 2 StartPhase 2 Start: A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With La
Phase 2 StartPhase 2 Start: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 1/2 Open-Label Intrathecal Administration of TSHA-105 to Determine the Safety and Efficacy i — GHRS Phase 2 Start | BioSniper